CTLA‐4‐Ig, a widely used biologic DMARD that operates by competitively inhibiting the CD28‐CD80/86 co‐stimulatory pathway, has been shown to have potential for preventing arthritis in clinical trials.34, 36. This evidence concerns the gene CTLA4 and arthritic joint disease.